Drug-drug Interaction between Pravastatin and Gemfibrozil (Antihyperlipidemic) with Gliclazide (Antidiabetic) in Rats
| Autor: | Kumar Ke, Sultanpur Cm, Reddy Ns, S. Satyanarayana, Kumar S |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Drug
medicine.medical_specialty media_common.quotation_subject drug–drug gliclazide interaction Pharmacology Diabetes mellitus Internal medicine medicine pharmacodynamics Gemfibrozil Gliclazide General Pharmacology Toxicology and Pharmaceutics media_common pravastatin business.industry Diabetes Metabolism medicine.disease Endocrinology Pharmacodynamics Concomitant gemfibrozil business Pravastatin medicine.drug |
| Zdroj: | Journal of Young Pharmacists : JYP |
| ISSN: | 0975-1505 |
| Popis: | Diabetes mellitus is a condition of increased blood glucose level in the body. Antihyperlipidemic drugs like statins and fibrates are widely used for prophylactic treatment in dyslipideamia and atherosclerosis. Diabetic dislipidemia exists with increased triglycerides, low HDL and high LDL levels. Hence, with oral hypoglycemic drugs, the addition of a lipid-lowering drug is necessary for controlling dislipidemia. In such a situation, there may be chances of drug-drug interactions between antidiabetic and antihyperlipidemic drugs. The present study is planned to evaluate the safety of gliclazide (antidiabetic) in the presence of pravastatin and gemfibrozil (antihyperlpidemic) in rats. Studies in normal and alloxan-induced diabetic rats were conducted with oral doses of gliclazide and their combination with pravastatin and gemfibrozil, with an adequate washout period in between the treatments. Blood samples were collected in rats by retroorbital puncture at 0, 1, 2, 3, 4, 6, 8, 10 and 12 h. All the blood samples were analyzed for glucose by GOD -POD. Gliclazide (½ TD) produced hypoglycemic activity in normal and diabetic rats, with peak activity at 2 and 8 h. Pravastatin (TD) + gemfibrozil (TD) combination treatment increased the hypoglycemic effect of gliclazide in normal rats or diabetic rats when administered together. The interaction observed due to inhibition of both the enzymes (CYP 450 2C9 and CYP 450 3A4) responsible for the metabolism of gliclazide showed increased half-life, which was seen in the present study. Because concomitant administration of gliclazide with provastatin and gemfibrozil in diabetes is associated with atherosclerosis, it should be contraindicated or used with caution. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|